Warner Chilcott acquires Dong-A's udenafil for US
This article was originally published in Scrip
Dong-A PharmTechhas licensed its erectile dysfunction product udenafil exclusively to Warner Chilcottfor development and marketing in the US. The oral PDE5 inhibitor was approved as Zydena in South Korea in 2005 and in Russia last year, and Dong-A has already completed a Phase II US development programme. The South Korean firm will receive undisclosed up-front and milestone payments from Warner Chilcott, which already markets a range of oral contraceptives and women's health products.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.